Average Upfront Payments in R&D-Stage Biotech Deals
Executive Summary
Over the past several years, average upfront payments at R&D-stage deals have remained fairly constant. But deals from the first half of 1997 show a significant drop in both average upfront payments and total equity payments, suggesting drug companies are moving even farther than they have in the past away from discover-stage deals.